SAN FRANCISCO BAY AREACalifornia., September 7, 2022 /PRNewswire/ — Rondo Therapeutics, a private biotechnology company advancing next-generation immuno-oncology platforms, announces the addition of Caroline Bertozzi, Ph.D., to its Scientific Council. Dr. Bertozzi is Professor of Chemistry and Director of the Sarafan ChEM-H Institute at Stanford University and is a world leader in the field of glycobiology, generating new insights into disease-associated changes in the patterns of cell surface glycosylation. Jessica Stark, Ph.D., an American Cancer Society postdoctoral fellow in the Bertozzi research group, also joins Rondo as a scientific consultant. Dr. Stark has pioneered new approaches to understanding the role of glycobiology in the functioning of the innate immune system.

Dr. Bertozzi has received numerous honors and awards for her achievements in research and teaching. She is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the German Academy of Sciences Leopoldina. Some of the most recent awards include the Welch Award in Chemistry (2022); The Dickson Prize in Medicine, University of Pittsburgh (2022); Dr. HP Heineken Prize in Biochemistry and Biophysics (2022); Wolf Prize (2022); AAAS Lifetime Mentorship Award (2022). Dr. Bertozzi is also an accomplished entrepreneur, having founded several biotechnology companies, including Palleon Pharma and Lycia Therapeutics.

“We are thrilled and privileged to work with Carolyn and Jessica in an exciting new area of ​​biology,” said Nathan Trinklin, Ph.D., co-founder and president of Rondo Therapeutics. “By combining their deep biological knowledge with Rondo’s unique ability to rapidly develop bispecific antibodies, we aim to create a new class of biologics with a unique mechanism of action.”

“We are excited to work with Rondo’s team to address glycobiology as an emerging frontier for immunotherapy,” said Jessica StarkPh.D., American Cancer Society Postdoctoral Fellow at Stanford University. “Through the development of a new class of bispecifics, we hope to make a difference for patients in multiple solid tumor indications.”

Dr. Bertozzi joins a group of highly distinguished scientists and clinicians on Rondo’s Scientific Advisory Board: james fordMD, professor of medicine, Stanford University; Alessandra Cesano, CMO, ESSA Pharmaceuticals; and Leonard PrestaPh.D., renowned protein engineer.

About Rondo Therapeutics

Rondo Therapeutics is a biopharmaceutical company exploring new frontiers in cancer treatment. Rondo is committed to advancing the field of immuno-oncology, with an emphasis on treating solid tumors that are unresponsive to current therapies. Our solution is to create a novel class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti-tumor response and overcome the suppressive tumor microenvironment.

Find out more at: www.rondotx.com.

SOURCE Rondo Therapeutic